治疗后CT LI-RADS分类:肝癌经单纯经动脉栓塞后总生存期的预测因素
本回顾性研究纳入2003年12月至2017年12月间接受经动脉栓塞(伴或不伴消融)的85例肝细胞癌患者,由两名放射科医师评估治疗前LI-RADS诊断分类、治疗后LR-TR分类及mRECIST缓解分类与总生存期的关联。结果显示治疗前LR-TIV(对比LR-5)及治疗后LR-TR Viable(对比LR-TR Nonviable)与总生存期相关,LR-TR Viable患者中位总生存期短于LR-TR Nonviable患者。
要点
- 治疗后LR-TR Viable(对比Nonviable)与更短总生存期相关,阅片时应重视LR-TR分类评估。
- 治疗前LR-TIV(对比LR-5)亦与总生存期相关。
- LR-TR分类的读者间一致性为中等至较好好(κ=0.68,95%CI 0.55-0.81)。
核心结论
- LR-TR分类与接受经动脉栓塞治疗的肝细胞癌患者总生存期呈强关联。
研究设计与样本
- 回顾性研究,纳入2003年12月至2017年12月间接受经动脉栓塞伴或不伴消融的未经治疗、1或2个病灶的肝细胞癌患者85例(中位年龄71岁,范围50-87;女性17例),由两名放射科医师(R1和R2)回顾治疗前和治疗后CT影像。
诊断标准与关键数值
- 采用Kaplan-Meier法和Cox比例风险回归评估治疗前和治疗后变量(包括治疗后LR-TR分类:Viable、Equivocal、Nonviable)与总生存期的关联;LR-TR分类读者间一致性κ=0.68(95%CI 0.55-0.81),LI-RADS分类读者间一致性κ=0.57(95%CI 0.35-0.78)。
临床应用与阅片要点
- 作者结论指出LR-TR分类与经动脉栓塞治疗的肝细胞癌患者总生存期呈强关联,阅片时应按LR-TR算法评估治疗后CT表现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The LI-RADS Treatment Response (LR-TR) algorithm was introduced in 2017 to assist radiologists in assessing hepatocellular carcinoma (HCC) response following locoregional therapy. The objective of this study was to evaluate the associations between pre-treatment LI-RADS diagnostic categories, post-treatment LR-TR categories, and mRECIST response categories with overall survival (OS) of patients with HCC.
METHODS: This retrospective study included untreated patients with one or two lesions who underwent transarterial embolization with or without concomitant ablation from December 2003 to December 2017. Two radiologists (R1 and R2) reviewed pre- and post-treatment CT imaging. Associations between pre- and post-treatment variables, including post-treatment LR-TR categories (Viable, Equivocal, Nonviable), with OS were assessed using the Kaplan-Meier method and Cox proportional hazards regression.
RESULTS: Eighty-five patients were included (median age = 71 years, range 50-87; 17 women). The median OS from first embolization was 43.92 months. Pre- and post-treatment tumor size, pre-treatment LR-TIV (compared with LR-5), and post-treatment LR-TR Viable (compared with LR-TR Nonviable) were associated with OS (p < 0.05 for all). Median OS was shorter for LR-TR Viable patients (R1, 25.64 months, 95% CI 18.58-35.70; R2, 26.43 months 95% CI 20.68-43.92) than for LR-TR Nonviable patients (64.21 months R1 and R2, 95% CI 42.71-92.45 and 36.30-94.09, respectively). mRECIST categories showed similar associations with OS. Inter-reader agreement was moderate for LI-RADS categories (κ = 0.57, 95% CI 0.35-0.78) and substantial for LR-TR categories (κ = 0.68, 95% CI 0.55-0.81).
CONCLUSIONS: LR-TR categories show a strong association with OS in HCC patients treated with transarterial embolization.
引用
- Ormiston WEL, Yarmohammadi H, Lobaugh S, et al. Post-treatment CT LI-RADS categories: predictors of overall survival in hepatocellular carcinoma post bland transarterial embolization. Abdom Radiol (NY). 2020. PMID: 32968863. doi:10.1007/s00261-020-02775-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。